资讯

Clinical Trials Arena on MSN15 天
Ractigen’s RAG-01 shows potential in treating non-muscle invasive bladder cancer
The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01.
pharmaphorum3 年
Lilly buys into MiNA's protein-boosting RNA tech in $1.25bn deal
UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in ...
Yahoo Finance16 天
Ractigen's RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data ...
NANTONG, China and MELBOURNE, Australia, March 24, 2025 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics ...
pharmaphorum15 天
MiNA’s gene-activating tech wins an AstraZeneca alliance
UK biotech MiNA Therapeutics’ RNA-based gene-activating technology has caught the eye of big pharma AstraZeneca. AZ has teamed up with the London-based startup to develop its small, activating ...
Business Wire20 天
MiNA Therapeutics Appoints Norbert Bischofberger, Ph.D., to its Board as Non-Executive ...
LONDON--(BUSINESS WIRE)--MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, has appointed Norbert Bischofberger, Ph.D., as a Non-Executive Director to its Board of ...